Development and validation of a circulating tumor cells-related signature focusing on biochemical recurrence and immunotherapy response in prostate cancer

• Published in: Heliyon 2023-12, Vol.9 (12), p.e22648, Article e22648
• Main Authors: Zhang, Xuezhou, Hong, Baoan, Sun, Zhipeng, Zhao, Jiahui, Li, Mingchuan, Wei, Dechao, Wang, Yongxing, Zhang, Ning
• Format: Article
• Language: English
• Subjects: biochemical recurrence; circulating tumor cells; Immunotherapy; prostate cancer; single cell data
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2023.e22648

Studies have shown that the circulating tumor cells (CTCs) play a key role for invasion and formation of distant metastases in prostate cancer (PCa). However, few CTCs-related genes (CRGs) have been developed for biochemical recurrence (BCR) prediction and clinical applications of PCa patients. Bioinformatics analysis with public PCa datasets were used to investigate the relationship between the differentially expressed CRGs and BCR. Lasso-COX regression analysis was used to constructed and validated a CRGs-based BCR prediction signature for PCa. Single-cell data were used to validate the expression levels of signature genes in different cell types and then explored the cell-cell communication relationships. Finally, the expression levels of signature genes were verified and the CRGs involved in immunotherapy response were further identified. Thirteen CRGs were differentially expressed and closely associated with BCR in PCa. Then we constructed and validated a BCR prediction signature for PCa patients based on 3 differentially expressed CRGs (EMID1, SPP1 and UBE2C), and the signature was an independent factor to predict BCR for PCa. Single-cell data showed the specific expression patterns of the signature genes, while the SPP1 pathway plays an important role in cell-cell communication. Further analyses suggested UBE2C was highly expressed in BCR group and high expression of UBE2C had a better response for patients who received immunotherapy. Moreover, the expression levels of UBE2C in CTCs were higher than other cells and tissues, indicated that UBE2C may affect the BCR event of PCa patients through CTCs. Our findings demonstrated that CRGs were significantly associated with BCR and immunotherapy efficacy in PCa and CRGs may influence the BCR event through CTCs. •The CRGs-based signature could predict BCR in PCa.•Single-cell data showed SPP1 pathway play an important role in cell-cell communication.•UBE2C was highly expressed in BCR group and CTCs.